Skip to main content
Premium Trial:

Request an Annual Quote

Immunai Acquires Dropprint Genomics

NEW YORK — Immune profiling firm Immunai said on Thursday that it has acquired single-cell genomics software company Dropprint Genomics for an undisclosed amount.

New York City-based Immunai, which has offices in San Francisco and Tel Aviv, said the acquisition is providing it with technologies San Francisco-based Dropprint has developed for handling the computational demands of large-scale single-cell sequencing and for more cost-effectively processing large numbers of patients samples.

Additionally, Dropprint, a Y Combinator-backed startup, has built a database of immune cell profiles from autoimmune and cancer patients that Immunai will incorporate into its Annotated Multi-omic Immune Cell Atlas (AMICA).

Dropprint's employees, including cofounders Meena Subramaniam and Rachel Gate, are joining Immunai's machine learning and computation biology team.

The acquisition comes a month after Immunai raised $60 million in a Series A financing round. The company said it has raised $80 million in funding to date.

For a more in-depth look at Immunais acquisition of Dropprint, click here.

The Scan

Tennessee's COVID-19 Sequencing

The Tennessean reports that a state lab there can now run its own genome sequencing analyses of SARS-CoV-2 samples.

Charged with Sanction Violations

A former professor has been charged with exporting genetic sequencing equipment to Iran in violation of US sanctions, the Miami Herald reports.

Prenetics to Go Public Through SPAC

Prenetics, a Hong Kong-based genomic and diagnostic company, is going public through a SPAC merger, according to 360Dx.

Nature Papers Examine Genomes of Centenarians, Transcription-Coupled DNA Repair

In Nature this week: analysis of centenarian genomes uncovers longevity-linked variants, and more.